Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours
Wang J, Barve M, Chiorean E, LoRusso P, Courtney K, Qi D, Bullington J, Sardone M, Chen J, Brooks C, Hoberman M, Mughal T, Bauer T. Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours. Annals Of Oncology 2020, 31: s485-s486. DOI: 10.1016/j.annonc.2020.08.678.Peer-Reviewed Original Research